Objective To investigate the association of liver stiffness measurement( LSM) and serum biochemical parameters with hepatic steatosis,liver inflammation,and liver fibrosis in patients with nonalcoholic steatohepatitis( NASH). Methods A total of 520 patients with NASH who were treated in The Fifth Medical Center of Chinese PLA General Hospital from January 2007 to December 2018 were enrolled,and according to body mass index( BMI) with a cut-off value of 28 kg/m2,the patients were divided into obese group with 151 patients and non-obese group with 369 patients. All patients underwent liver biopsy,and LSM was measured within 3 days before biopsy. Serum biochemical parameters and general clinical data were collected before liver biopsy,and the noninvasive indices aspartate aminotransferase to platelet ratio index( APRI) and fibrosis-4( FIB-4) were calculated. The t-test was used for comparison of normally distributed continuous between groups,the nonparametric Mann-Whitney U test was used for comparison of non-normally distributed continuous between groups; the chi-square test was used for comparison of categorical data between groups. A Spearman rank correlation analysis was also performed. Results Alanine aminotransferase( ALT),aspartate aminotransferase,LSM,controlled attenuation parameter( CAP),spleen length,and APRI gradually increased with the increase in BMI( all P < 0. 05). The Spearman correlation analysis showed that LSM,ALT,BMI,and CAP were positively correlated with the degree of hepatic steatosis( r = 0. 263,0. 327,0. 184,and 0. 452,all P < 0. 05); LSM,ALT,and CAP were positively correlated with the degree of liver inflammation( r = 0. 357,0. 278,and 0. 121,all P < 0. 05); LSM,ALT,BMI,and CAP were positively correlated with the degree of liver fibrosis( r = 0. 500,0. 216,0. 248,and 0. 101,all P < 0. 05); age was negatively correlated with the degree of hepatic steatosis,liver inflammation,and liver fibrosis( r =-0. 344,-0. 129,and-0. 163,all P < 0. 05). Conclusion LSM,CAP,ALT,and age are significantly correlated with the degree of liver inflammation,liver fibrosis,and hepatic steatosis in NASH patients,and therefore,they can be used in noninvasive diagnostic and predictive models to access the severity of liver injury.
[1] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.
|
[2] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association,Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:2006[J]. Mod Digest Interv,2007,12(4):266-268.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病诊疗指南(2006年2月修订)[J].现代消化及介入诊疗,2007,12(4):266-268.
|
[3] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association,Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
|
[4] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84.
|
[5] VILAR-GOMEZ E,CALZADILLA-BERTOT L,WAI-SUN WONG V,et al. Fibrosis severity as a determinant of causespecific mortality in patients with advanced nonalcoholic fatty liver disease:A multi-national cohort study[J]. Gastroenterology,2018,155(2):443-457.
|
[6] BEDOSSA P,PATEL K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease[J].Gastroenterology,2016,150(8):1811-1822.
|
[7] WONG VW,ADAMS LA,de LEDINGHEN V,et al. Noninvasive biomarkers in NAFLD and NASH-current progress and future promise[J]. Nat Rev Gastroenterol Hepatol,2018,15(8):461-478.
|
[8] BRUNT EM,JANNEY CG,di BISCEGLIE AM,et al. Nonalcoholic steatohepatitis:A proposal for grading and staging the histological lesions[J]. Am J Gastroenterol,1999,94(9):2467-2474.
|
[9] KLEINER DE,BRUNT EM,van NATTA M,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology,2005,41(6):1313-1321.
|
[10] ADAMS LA,FELDSTEIN AE. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis[J]. J Dig Dis,2011,12(1):10-16.
|
[11] LEUNG JC,LOONG TC,WEI JL,et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J]. Hepatology,2017,65(1):54-64.
|
[12] WANG Y,WANG B,SHEN F,et al. Body mass index and risk of primary liver cancer:A meta-analysis of prospective studies[J]. Oncologist,2012,17(11):1461-1468.
|
[13] WONG VW,WONG GL,YEUNG JC,et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram:A prospective cohort study[J]. Hepatology,2016,63(3):754-763.
|
[14] POYNARD T,RATZIU V,CHARLOTTE F,et al. Diagnostic value of biochemical markers(Nash Test)for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease[J]. BMC Gastroenterol,2006,6:34.
|
[15] PALEKAR NA,NAUS R,LARSON SP,et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease[J]. Liver Int,2006,26(2):151-156.
|
[16] ULITSKY A,ANANTHAKRISHNAN AN,KOMOROWSKI R,et al. A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients[J]. Obes Surg,2010,20(6):685-691.
|
[17] FU YM,JI D,WANG CY,et al. SAT-284-Diagnostic performance of transient elastography on liver fibrosis of patients with non-alcoholic fat hepatitis[J]. J Hepatol,2019,70(1):e761.
|
[18] LIANG J,ZHONG BY,TANG Y,et al. Study on liver fibrosis examination in nonalcoholic fatty liver disease[J]. Chin Health Standard Manage,2017,8(17):110-113.(in Chinese)梁健,钟碧莹,汤茵,等.肝纤维化检测在非酒精性脂肪肝诊断中的应用研究[J].中国卫生标准管理,2017,8(17):110-113.
|
[19] LENG XJ,YAN XB. Efficiency of FibroTouch in evaluating liver fibrosis degree in nonalcoholic fatty liver disease patients with different levels of body mass index[J]. J Clin Hepatol,2018,34(9):1891-1895.(in Chinese)冷雪君,颜学兵.FibroTouch对不同BMI水平非酒精性脂肪性肝病患者肝纤维化程度的评估比较[J].临床肝胆病杂志,2018,34(9):1891-1895.
|
[20] FU YM,JI D,XIONG YR,et al. Diagnostic performance of liver stiffness measurement on liver fibrosis of patients with nonalcoholic steatohepatitis[J]. Med J Chin PLA,2019,44(8):671-675.(in Chinese)付懿铭,纪冬,熊艺茹,等.肝脏弹性检测对非酒精性脂肪性肝炎肝纤维化分期的诊断效能[J].解放军医学杂志,2019,44(8):671-675.
|
[21] XIAO G,ZHU S,XIAO X,et al. Comparison of laboratory tests,ultrasound,or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease:A meta-analysis[J]. Hepatology,2017,66(5):1486-1501.
|
[22] SHEN F,ZHENG RD,MI YQ,et al. A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver[J]. Chin J Hepatol,2014,22(12):926-931.(in Chinese)沈峰,郑瑞丹,宓余强,等.受控衰减参数诊断脂肪肝的临界值初探:一项多中心临床研究[J].中华肝脏病杂志,2014,22(12):926-931.
|
[23] SHEN F,XU ZJ,PAN Q,et al. Influencing factors and reproducibility of controlled attenuation parameters in the evaluation of fatty liver disease using FibroScan[J]. J Pract Hepatol,2013,16(1):59-62.(in Chinese)沈峰,徐正婕,潘勤,等.FibroScan实施受控衰减参数评价脂肪肝的影响因素及重复性分析[J].实用肝脏病杂志,2013,16(1):59-62.
|
[24] YATSUJI S,HASHIMOTO E,TOBARI M,et al. Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis[J]. Hepatol Res,2007,37(12):1034-1043.
|
1. | 苏润林,王林燕,时丽. 肝功能酶学指标联合血脂指标在酒精性与非酒精性脂肪肝中的鉴别. 吉林医学. 2025(01): 126-128 . ![]() | |
2. | 孔焱,李晓慧,王辉,李岩,孙悦,苗强. 间接法建立新疆克拉玛依地区常规肝功能和血脂生化项目参考区间. 国际检验医学杂志. 2024(07): 858-861+866 . ![]() | |
3. | 郭永成. 血脂及肝功能指标在脂肪肝临床诊断中的价值. 中国医药指南. 2024(11): 87-89 . ![]() | |
4. | 安薪宇,乔杰,胡灵溪,王荣琦,南月敏. GP73对慢性肝病患者肝纤维化诊断价值的研究. 中华内科杂志. 2023(01): 49-53 . ![]() | |
5. | 张珊,陈松海,刘妍,王春艳,付懿铭,陆荫英,纪冬,陈国凤. 非酒精性脂肪性肝病对乙肝病毒相关肝细胞癌患者生存的影响. 解放军医学杂志. 2023(02): 157-162 . ![]() | |
6. | 贺沂. 超声诊断酒精肝与脂肪肝的临床价值. 影像研究与医学应用. 2023(22): 119-121 . ![]() | |
7. | 秦宸. 临床检验生化指标在不同类型肝病患者诊断中的应用分析. 现代诊断与治疗. 2022(02): 237-239+242 . ![]() | |
8. | 付懿铭,王春艳,李忠斌,王建军,陈松海,杨武才,陈国凤,纪冬. 受控衰减参数对非酒精性脂肪性肝病患者肝脂肪变性分级的诊断价值. 解放军医学杂志. 2022(06): 593-598 . ![]() | |
9. | 姜寿清. B超诊断脂肪肝与血液生化检查对照分析. 现代医用影像学. 2022(06): 1151-1153 . ![]() | |
10. | 杨春香. 肝功指标、血脂血清学指标水平检验在脂肪肝诊断中的临床价值. 系统医学. 2022(13): 27-31 . ![]() | |
11. | 李金强,王环君,谢青,黎晓武,刘凤娥,皮银珍. 补充维生素D治疗对非酒精性脂肪性肝炎患者生化指标、IL-18、IL-37及肝纤维化、脂肪变的影响. 湖南师范大学学报(医学版). 2022(02): 117-120 . ![]() | |
12. | 李亚雪,薛红元,武晓静,高强,许栩. 超声SWE、SWD技术在代谢功能障碍相关性脂肪肝病中的初步研究. 中国超声医学杂志. 2022(10): 1128-1131 . ![]() | |
13. | 袁维,王炳予,杨磊,张雅丽,袁星星. 芪参汤治疗非酒精性脂肪性肝炎的临床疗效观察及对肠道菌群的影响. 中国中西医结合消化杂志. 2021(06): 383-391 . ![]() | |
14. | 胡先姣. 肝功能指标与血脂指标在脂肪肝诊断中的应用分析. 现代医学与健康研究电子杂志. 2021(14): 106-108 . ![]() | |
15. | 王艺婷,李雪文,邢东洋,何冰,许建成. 间接法建立长春地区成人肝功能四项生化指标参考区间. 临床肝胆病杂志. 2021(09): 2161-2166 . ![]() | |
16. | 姚超,裴滢. 肝病患者血清检验指标改变的临床价值及准确性分析. 中国社区医师. 2021(36): 109-110 . ![]() |